1 month ago
AOL
The new diabetes drug Mounjaro was behind Kay’s weight loss, but when the manufacturer, Eli Lilly, changed its coupon terms her transformation became unaffordable — and unsustainable. Mounjaro, the name brand for tirzepatide, is one of a new class of nutrient-stimulated hormone-based therapies that’s changed the way type 2 diabetes (T2D) is treated. In a separate study, Novo-Nordisk’s celebrity-endorsed Ozempic, which targets only GLP-1, showed an average weight reduction of 16.9 percent. The conflict, which has been exacerbated by shortages of Mounjaro and two of its GLP-1 predecessors, Ozempic and Trulicity, has been intensified on social media. In November, without warning, Eli Lilly then changed the terms of the coupon, resulting in mass confusion and vitriolic encounters both online and in pharmacies nationwide.
Continue reading...
